ARPO - Aerpio Pharmaceuticals: Is This Stock A Buy Or Sell? Not Until The Merger Is Over
- Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company that is developing compounds that activate Tie2 for various indications but has recently entered into a merger with privately-held Aadi Bioscience.
- Aadi is a private clinical-stage biopharmaceutical company developing precision therapies for genetically defined cancers with alterations in mTOR pathway genes and currently awaiting NDA results.
- Aerpio and Aadi entered into an agreement on May 2021 for a merger where Aerpio stockholders will only own 14.7% of the new entity expected to finalize in 2H 2021.
- Aerpio and Aadi's consolidated financials outline an expected post-merger cash position of $182.6M (incl. of PIPE) with sales expected to reach $7M in 2023 growing up to $2.5B by 2030.
- In summary, the author projects Aerpio Pharmaceuticals, Inc. as a "hold" until after the Merger.
For further details see:
Aerpio Pharmaceuticals: Is This Stock A Buy Or Sell? Not Until The Merger Is Over